The functional validation of genetic variants of uncertain significance (VUS) found in PID patients by next-generation sequencing has traditionally been carried out in model systems that are susceptible to artefact. We use CRISPR correction of primary human T lymphocytes to demonstrate that a specific variant in an IL-6R deficient patient is causative for their condition.
INTRODUCTION
Primary immunodeficiency diseases (PIDs) form a diverse group of genetic disorders caused by defects in the development or function of the immune system, which predispose to infectious pathogens but also autoimmune disease and malignancy (1) . To date, more than 350 distinct disorders have been described, with a similar number of individual genes implicated (2) . Obtaining an accurate diagnosis has important consequences for prognosis, treatment and genetic counselling (3) . Traditional PID diagnostic strategies encompass clinical evaluation, and standard laboratory screening tests, as well as testing of specific pathways, for example assays to evaluate neutrophil oxidative burst, or T cell receptor signalling pathways (4) . This approach enables clinicians to categorise the patient's clinical and immunological phenotype and identify one or more candidate genes for Sanger sequencing (1)(5). This phenotype-based approach comes with a significant time and resource cost. It is dependent on obtaining viable cells from patients and training laboratory staff to perform a diverse range of techniques. Transfer of patient samples can impact cell viability and impair physiological responses, compromising the accuracy of diagnostic tests (1) . Alternatively, next-generation sequencing (NGS) methods are becoming increasingly accessible in the clinical laboratory setting. These rapid, accurate, and relatively low cost methods allow a high-throughput, genotype-based approach to molecular diagnosis (5) . Whole genome sequencing (WGS) has been able to demonstrate the broad range of phenotypes caused by monogenic mutations and has facilitated discovery of multigenic PIDS and risk factor genes/modifier mutations. In addition, high coverage WGS allows identification of somatic variants in subpopulations of immune cells (1) .
RESULTS AND DISCUSSION
In the recently described IL-6R deficiency, WGS identified uniparental isodisomy of chromosome 1 in a patient with PID (9). Within chromosome 1, a rare frameshifting homozygous mutation ([c.548del] + [c.548del], chromosome 1, exon 4) in the IL-6R gene leading to a premature stop codon and truncated protein was identified. The IL-6R is central to IL-6 signalling -IL-6 binding to IL-6R leads to activation of the JAK/STAT signal transduction pathway leading to STAT3dependent growth and differentiation. The patient cells shown impaired IL-6 induced pSTAT3 and ectopic expression of wild-type IL-6R, restored STAT3 responses to IL-6. However, this experiment does not exclude the possibility that other variants in the highly atypical chromosome 1 of this patient, led to their impaired IL-6R function. Genome editing can precisely determine whether the specific mutation led to the loss of IL-6R function.
A single guide RNA (sgRNA) was designed and assessed computationally for predicted on-target and off-target activity using DESKGEN software package (www.deskgen.com). A 200 bp singlestranded donor template (ssODN) was designed to be homologous with the target DNA 100 bp either side of the mutation. The template contains a 1 bp insertion, designed to correct the patient's 1 bp deletion of a guanine. Three phosphorothioate (PS) inter-nucleotide linkage modifications, thought to increase HDR efficiency by stabilising the ssODN, were incorporated at the 5' and 3' ends with a sulfurizing reagent (10) . To circumvent recutting of the corrected patient DNA by excess ribonucleoprotein (RNP), a silent mutation was created in the sgRNA protospacer adjacent motif (PAM) site in the HDR template. T cells (CD3 + T cells) were first isolated from the patient's PBMCs. The sgRNA designed and tested to target IL-6R and Spy Cas9 complexed into a ribonucleoprotein (RNP) and the ssODN designed to correct IL-6R was electroporated into the patient T cells. Genomic (g)DNA was extracted from half of the cells and Sanger Sequenced (11) .
The chromatogram from the edited patient sequencing trace in Figure 1 Accompanying the increased application of WGS in clinical diagnostics comes the identification of a growing number of potentially pathogenic genetic variants requiring functional assessment and validation. This CRISPR-Cas9 protocol offers a strategy for rapid assessment and confirmation of causality of VUS in genes involved in signal transduction pathways in immune cells, circumventing viral delivery of CRISPR components. This brings the opportunity to understand the functional impact of genetic change in a relevant model system and it leads to the possibility of therapeutic applications using cell and gene-based therapies. The data here from a model system confirms successful CRISPR-Cas9 correction of a novel genetic anomaly in the IL-6R gene and restoration of receptor function, confirming that the patient's lack of STAT3 response is caused by their rare IL-6R variant. Furthermore, the lack of STAT3 signalling caused by the variant helps to explain the clinical phenotype of the patient. Ensuring that the approach is applicable when allele-specific editing is required is key to building this work into a functional genomics platform that is broadly applicable to a range of pathogenic mutations.
Probing genetic function using CRISPR knock-out via the NHEJ pathway is well adopted whereas using CRISPR knock-in via the HDR pathway is less well established and is less commonly utilized due to low efficiency (13) . Due to the limited number of patient cells, a biochemical assay was used to detect restoration of STAT3 because this requires fewer cells. Quantifying data using Western Blotting is difficult and comparing editing efficiency from Sanger sequencing data to the functional rescue of IL6R is unreliable. Several developments could be made here to enhance the data. A functional single cell-based assay to detect restoration of STAT3 signalling in CRISPR corrected cells would provide more quantifiable results. Single-cell cloning of the edited population of cells could provide paired genotypic and functional information about independently edited clones and downstream experimentation on edited clones such as investigation of transcription factors and expression of genes involved in the inflammatory response. Currently, the data shows the proportion of alleles in the pool of sequences that have been corrected. Introducing genetic markers to purify the cells that have been homogeneously edited would be useful for functional interrogation and potential therapeutic applications.
MATERIALS AND METHODS

Cell culture
All cell lines used were authenticated by Short Tandem Repeat (STR) DNA profiling and tested for mycoplasma contamination regularly. All antibodies were diluted in 10 mL of solution.
Primary and secondary antibodies used for Western
LI-COR Odyssey CLx
The proteins were detected using infrared imaging on the Odyssey® CLx Imaging System to detect 680 nm and 800 nm fluorescence on the same membrane. Image Studio™ Software was used for densitometry.
